Skip to main content

Table 1 Patients’ demographic and clinical characteristics

From: Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

  Group A (SST)
n = 100
Group B (LST)
n = 100
p
Mean age (years) 52.4 ± 16.2
(range 18–89)
54 ± 15.3
(range 18–81)
0.458
Gender
 - Female
 - Male
55%
45%
60%
40%
0.567
Smoking habits 8% 8% 1
Alcohol consumption 19% 10% 0.107
Indication(s) for H. pylori eradication
 - Non-ulcer dyspepsia
 - Peptic ulcer
 - GERD/chronic use of PPI
 - Before bariatric surgery
 - Anemia or thrombocytopenia
 - Familial history of gastric cancer
63%
14%
11%
9%
2%
1%
72%
10%
11%
---
7%
---
0.307
0.452
1
---
0.229
---
Nitroimidazole antibiotic
 - Tinidazole
 - Metronidazole
53%
47%
81%
19%
0.001
Metronidazole dosage
 - 500 mg 12–12 h (1000 mg)
 - 500 mg 8–8 h (1500 mg)
29,8%
70,2%
21,1%
79,9%
0.554
PPI 1st or 2nd generation
 - Omeprazole / Pantoprazole / Lansoprazole
 - Esomeprazole / Rabeprazole
81%
19%
89%
11%
0.165
PPI dosage
 - Full-dose
 - Half-dose
91%
9%
88%
12%
0.645
Prescribing Physician
 - Gastroenterologist
 - Non-Gastroenterologist
79%
21%
94%
6%
0.002
  1. SST standard sequential treatment, LST levofloxacin-based sequential treatment, GERD gastroesophageal reflux disease, PPI proton-pump inhibitor